1319716-41-0

Basic information

• Product Name: 7-Hydroxy-2-aza-spiro[4.4]nonane-2-carboxylic acid tert-butyl ester
• Synonyms: 7-Hydroxy-2-aza-spiro[4.4]nonane-2-carboxylic acid tert-butyl ester;tert-butyl 7-hydroxy-2-azaspiro[4.4]nonane-2-carboxylate;2-AZASPIRO[4.4]NONANE-2-CARBOXYLIC ACID, 7-HYDROXY-, 1,1-DIMETHYLETHYL ESTER
• CAS NO: 1319716-41-0
• Molecular Formula: C13H23NO3
• Molecular Weight: 241.33
• Mol File: 1319716-41-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 7-Hydroxy-2-aza-spiro[4.4]nonane-2-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Hydroxy-2-aza-spiro[4.4]nonane-2-carboxylic acid tert-butyl ester(1319716-41-0)
• EPA Substance Registry System: 7-Hydroxy-2-aza-spiro[4.4]nonane-2-carboxylic acid tert-butyl ester(1319716-41-0)

Safety Data

• Hazardous Substances Data: 1319716-41-0(Hazardous Substances Data)

Usage

General Description

7-Hydroxy-2-aza-spiro[4.4]nonane-2-carboxylic acid tert-butyl ester is a chemical compound with the molecular formula C12H23NO3. It is a spiro compound, meaning it contains a cyclic structure with a central atom bound to two or more other atoms in a way that forms a ring. The tert-butyl ester group in the compound indicates the presence of a particular chemical group that includes a tert-butyl group, which is a branched alkyl group. This chemical may have potential applications in pharmaceutical and organic synthesis due to its unique spiro and ester functionalities. It is important to handle and use this compound in accordance with proper safety guidelines and precautions.

Upstream product

• 1319716-35-2 tert-butyl 3,3-diallyl-2-oxopyrrolidine-1-carboxylate 
• 1319716-36-3 tert-butyl 1-oxo-2-azaspiro[4.4]nonan-7-ene-2-carboxylate 
• 85909-08-6 tert-butyl 2-oxopyrrolidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1319716-42-1 tert-butyl 7-oxo-2-azaspiro[4.4]nonane-2-carboxylate 

Relevant articles and documents

DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS

Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

Substituted heteroaryl compounds and compositions and uses thereof

The invention provides a substituted ceteroary compound as well as a composition and a purpose thereof. The substituted ceteroary compound is a compound shown as a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the pharmaceutically acceptable salt of the compound shown as the formula (I) and is used for regulating diseases or disorders mediated by one kind or various kinds of Janus kinase activities. The invention also provides a medicine composition containing the compound and a method of treating or alleviating the disease or disorder degree of a patient by inhibiting the Janus kinase activity.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides new heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of JAK-mediated diseases. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated diseases.